Skip to main content
Top
Published in: Virology Journal 1/2014

Open Access 01-12-2014 | Short report

Plaque reduction neutralization antibody test does not accurately predict protection against dengue infection in Ratchaburi cohort, Thailand

Authors: Chukiat Sirivichayakul, Arunee Sabchareon, Kriengsak Limkittikul, Sutee Yoksan

Published in: Virology Journal | Issue 1/2014

Login to get access

Abstract

Background

The plaque reduction neutralization test (PRNT) is currently the best and most widely accepted approach to measuring virus-neutralizing and protective antibodies to dengue virus, and in assessing the immunogenicity of a dengue vaccine. However, the correlation between presence of dengue-neutralizing antibody and protection from infection is not absolute.

Findings

In a cohort study in Ratchaburi Province, Thailand, 48 subjects with serologically confirmed symptomatic dengue infection were tested for pre-existing dengue neutralizing antibody using PRNT. Nine subjects had quite high pre-existing PRNT50 titers (titer >90) to subsequent infecting dengue serotypes, but still had symptomatic infections.

Conclusion

This report provides evidence that PRNT may not be a good test for predicting protection against subsequent dengue infection.
Literature
1.
go back to reference Roehrig JT, Hombach J, Barrett AD: Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses. Virol Immunol 2008, 21: 123-132. 10.1089/vim.2008.0007CrossRef Roehrig JT, Hombach J, Barrett AD: Guidelines for plaque-reduction neutralization testing of human antibodies to dengue viruses. Virol Immunol 2008, 21: 123-132. 10.1089/vim.2008.0007CrossRef
2.
go back to reference Reisler RB, Danner DK, Gibbs PH: Immunogenicity of an inactivated Japanese encephalitis vaccine (JE-VAX) in humans over 20 years at USAMRIID: using PRNT50 as an endpoint for immunogenicity. Vaccine 2010, 28: 2436-2441. 10.1016/j.vaccine.2009.12.080PubMedCrossRef Reisler RB, Danner DK, Gibbs PH: Immunogenicity of an inactivated Japanese encephalitis vaccine (JE-VAX) in humans over 20 years at USAMRIID: using PRNT50 as an endpoint for immunogenicity. Vaccine 2010, 28: 2436-2441. 10.1016/j.vaccine.2009.12.080PubMedCrossRef
3.
go back to reference Eder S, Dubischar-Kastner K, Firbas C, Jelinek T, Jilma B, Kaltenboeck A, Knappik M, Kollaritsch H, Kundi M, Paulke-Korinek M, Schuller E, Klade CS: Long term immunity following a booster dose of the inactivated Japanese Encephalitis vaccine IXIARO®, IC51. Vaccine 2011, 29: 2607-2612. 10.1016/j.vaccine.2011.01.058PubMedCrossRef Eder S, Dubischar-Kastner K, Firbas C, Jelinek T, Jilma B, Kaltenboeck A, Knappik M, Kollaritsch H, Kundi M, Paulke-Korinek M, Schuller E, Klade CS: Long term immunity following a booster dose of the inactivated Japanese Encephalitis vaccine IXIARO®, IC51. Vaccine 2011, 29: 2607-2612. 10.1016/j.vaccine.2011.01.058PubMedCrossRef
4.
go back to reference Feroldi E, Pancharoen C, Kosalaraksa P, Watanaveeradej V, Phirangkul K, Capeding MR, Boaz M, Gailhardou S, Bouckenooghe A: Single-dose, live-attenuated Japanese encephalitis vaccine in children aged 12–18 months: randomized, controlled phase 3 immunogenicity and safety trial. Hum Vaccin Immunother 2012, 8: 929-937. 10.4161/hv.20071PubMedCrossRef Feroldi E, Pancharoen C, Kosalaraksa P, Watanaveeradej V, Phirangkul K, Capeding MR, Boaz M, Gailhardou S, Bouckenooghe A: Single-dose, live-attenuated Japanese encephalitis vaccine in children aged 12–18 months: randomized, controlled phase 3 immunogenicity and safety trial. Hum Vaccin Immunother 2012, 8: 929-937. 10.4161/hv.20071PubMedCrossRef
5.
go back to reference Kochel TJ, Raviprakash K, Hayes CG, Watts DM, Russell KL, Gozalo AS, Phillips IA, Ewing DF, Murphy GS, Porter KR: A dengue virus serotype-1 DNA vaccine induces virus neutralizing antibodies and provides protection from viral challenge in Aotus monkeys. Vaccine 2000, 18: 3166-3173. 10.1016/S0264-410X(00)00105-5PubMedCrossRef Kochel TJ, Raviprakash K, Hayes CG, Watts DM, Russell KL, Gozalo AS, Phillips IA, Ewing DF, Murphy GS, Porter KR: A dengue virus serotype-1 DNA vaccine induces virus neutralizing antibodies and provides protection from viral challenge in Aotus monkeys. Vaccine 2000, 18: 3166-3173. 10.1016/S0264-410X(00)00105-5PubMedCrossRef
6.
go back to reference Sabchareon A, Lang J, Chanthavanich P, Yoksan S, Forrat R, Attanath P, Sirivichayakul C, Pengsaa K, Pojjaroen-Anant C, Chambonneau L, Saluzzo JF, Bhamarapravati N: Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children. Pediatr Infect Dis J 2004, 23: 99-109. 10.1097/01.inf.0000109289.55856.27PubMedCrossRef Sabchareon A, Lang J, Chanthavanich P, Yoksan S, Forrat R, Attanath P, Sirivichayakul C, Pengsaa K, Pojjaroen-Anant C, Chambonneau L, Saluzzo JF, Bhamarapravati N: Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children. Pediatr Infect Dis J 2004, 23: 99-109. 10.1097/01.inf.0000109289.55856.27PubMedCrossRef
8.
go back to reference Guy B, Saville M, Lang J: Development of Sanofi Pasteur tetravalent dengue vaccine. Hum Vaccin 2010,6(9):696-705. 10.4161/hv.6.9.12739CrossRef Guy B, Saville M, Lang J: Development of Sanofi Pasteur tetravalent dengue vaccine. Hum Vaccin 2010,6(9):696-705. 10.4161/hv.6.9.12739CrossRef
9.
go back to reference Sabchareon A, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, Jiwariyavej V, Dulyachai W, Pengsaa K, Margolis HS, Letson GW: Dengue infection in children in Ratchaburi, Thailand: a cohort study. I. Epidemiology of symptomatic acute dengue infection in children, 2006–2009. PLoS Negl Trop Dis 2012, 6: e1732. 10.1371/journal.pntd.0001732PubMedPubMedCentralCrossRef Sabchareon A, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, Jiwariyavej V, Dulyachai W, Pengsaa K, Margolis HS, Letson GW: Dengue infection in children in Ratchaburi, Thailand: a cohort study. I. Epidemiology of symptomatic acute dengue infection in children, 2006–2009. PLoS Negl Trop Dis 2012, 6: e1732. 10.1371/journal.pntd.0001732PubMedPubMedCentralCrossRef
10.
go back to reference World Health Organization: Dengue hemorrhagic fever: diagnosis, treatment, prevention and control. Geneva: WHO; 1997. World Health Organization: Dengue hemorrhagic fever: diagnosis, treatment, prevention and control. Geneva: WHO; 1997.
11.
go back to reference Innis BL, Nisalak A, Nimmannitya S, Kusalerdchariya S, Chongswasdi V, Suntayakorn S, Puttisri P, Hoke CH: An enzyme-linked immunosorbent assay to characterize dengue infections when dengue and Japanese encephalitis co-circulate. Am J Trop Med Hyg 1989, 40: 418-427.PubMed Innis BL, Nisalak A, Nimmannitya S, Kusalerdchariya S, Chongswasdi V, Suntayakorn S, Puttisri P, Hoke CH: An enzyme-linked immunosorbent assay to characterize dengue infections when dengue and Japanese encephalitis co-circulate. Am J Trop Med Hyg 1989, 40: 418-427.PubMed
12.
go back to reference Rosen L: The use of Toxorhynchites mosquitoes to detect and propagate dengue and other arboviruses. Am J Trop Med Hyg 1981, 30: 177-183.PubMed Rosen L: The use of Toxorhynchites mosquitoes to detect and propagate dengue and other arboviruses. Am J Trop Med Hyg 1981, 30: 177-183.PubMed
13.
go back to reference Russell PK, Nisalak A, Sukhavachana P, Vivona S: A plaque reduction test for dengue virus neutralizing antibodies. J Immunol 1967, 99: 285-290.PubMed Russell PK, Nisalak A, Sukhavachana P, Vivona S: A plaque reduction test for dengue virus neutralizing antibodies. J Immunol 1967, 99: 285-290.PubMed
14.
go back to reference Sabin AB: Research on dengue during World War II. Am J Trop Med Hyg 1952, 1: 30-50.PubMed Sabin AB: Research on dengue during World War II. Am J Trop Med Hyg 1952, 1: 30-50.PubMed
15.
go back to reference Endy TP, Nisalak A, Chunsuttitwat S, Vaughn DW, Green S, Ennis FA, Rothman AL, Libraty DH: Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. J Infect Dis 2004, 189: 990-1000. 10.1086/382280PubMedCrossRef Endy TP, Nisalak A, Chunsuttitwat S, Vaughn DW, Green S, Ennis FA, Rothman AL, Libraty DH: Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. J Infect Dis 2004, 189: 990-1000. 10.1086/382280PubMedCrossRef
16.
go back to reference Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, Jiwariyavej V, Dulyachai W, Pengsaa K, Wartel TA, Moureau A, Saville M, Bouckenooghe A, Viviani S, Tornieporth NG, Lang J: Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 2012, 380: 1559-1567. 10.1016/S0140-6736(12)61428-7PubMedCrossRef Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, Jiwariyavej V, Dulyachai W, Pengsaa K, Wartel TA, Moureau A, Saville M, Bouckenooghe A, Viviani S, Tornieporth NG, Lang J: Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 2012, 380: 1559-1567. 10.1016/S0140-6736(12)61428-7PubMedCrossRef
17.
go back to reference Rodrigo WW, Jin X, Blackley SD, Rose RC, Schlesinger JJ: Differential enhancement of dengue virus immune complex infectivity mediated by signaling-competent and signaling-incompetent human Fcgamma RIA (CD64) or FcgammaRIIA (CD32). J Virol 2006, 80: 10128-10138. 10.1128/JVI.00792-06PubMedPubMedCentralCrossRef Rodrigo WW, Jin X, Blackley SD, Rose RC, Schlesinger JJ: Differential enhancement of dengue virus immune complex infectivity mediated by signaling-competent and signaling-incompetent human Fcgamma RIA (CD64) or FcgammaRIIA (CD32). J Virol 2006, 80: 10128-10138. 10.1128/JVI.00792-06PubMedPubMedCentralCrossRef
18.
go back to reference Moi ML, Lim CK, Chua KB, Takasaki T, Kurane I: Dengue virus infection-enhancing activity in serum samples with neutralizing activity as determined by using FcγR-expressing cells. PLoS Negl Trop Dis 2012, 6: e1536. 10.1371/journal.pntd.0001536PubMedPubMedCentralCrossRef Moi ML, Lim CK, Chua KB, Takasaki T, Kurane I: Dengue virus infection-enhancing activity in serum samples with neutralizing activity as determined by using FcγR-expressing cells. PLoS Negl Trop Dis 2012, 6: e1536. 10.1371/journal.pntd.0001536PubMedPubMedCentralCrossRef
19.
go back to reference Thomas SJ, Nisalak A, Anderson KB, Libraty DH, Kalayanarooj S, Vaughn DW, Putnak R, Gibbons RV, Jarman R, Endy TP: Dengue plaque reduction neutralization test (PRNT) in primary and secondary dengue virus infection: how alteration in assay conditions impact performance. Am J Trop Med Hyg 2009, 81: 825-833. 10.4269/ajtmh.2009.08-0625PubMedPubMedCentralCrossRef Thomas SJ, Nisalak A, Anderson KB, Libraty DH, Kalayanarooj S, Vaughn DW, Putnak R, Gibbons RV, Jarman R, Endy TP: Dengue plaque reduction neutralization test (PRNT) in primary and secondary dengue virus infection: how alteration in assay conditions impact performance. Am J Trop Med Hyg 2009, 81: 825-833. 10.4269/ajtmh.2009.08-0625PubMedPubMedCentralCrossRef
20.
go back to reference Rainwater-Lovett K, Rodriguez-Barraquer I, Cummings DA, Lessler J: Variation in dengue virus plaque reduction neutralization testing: systematic review and pool analysis. BMC Infect Dis 2012, 12: 233. 10.1186/1471-2334-12-233PubMedPubMedCentralCrossRef Rainwater-Lovett K, Rodriguez-Barraquer I, Cummings DA, Lessler J: Variation in dengue virus plaque reduction neutralization testing: systematic review and pool analysis. BMC Infect Dis 2012, 12: 233. 10.1186/1471-2334-12-233PubMedPubMedCentralCrossRef
21.
go back to reference Chen SP: Molecular evolution and epidemiology of four serotypes of dengue virus in Thailand from 1973 to 2007. Epidemiol Infect 2012, 14: 1-6. Chen SP: Molecular evolution and epidemiology of four serotypes of dengue virus in Thailand from 1973 to 2007. Epidemiol Infect 2012, 14: 1-6.
Metadata
Title
Plaque reduction neutralization antibody test does not accurately predict protection against dengue infection in Ratchaburi cohort, Thailand
Authors
Chukiat Sirivichayakul
Arunee Sabchareon
Kriengsak Limkittikul
Sutee Yoksan
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Virology Journal / Issue 1/2014
Electronic ISSN: 1743-422X
DOI
https://doi.org/10.1186/1743-422X-11-48

Other articles of this Issue 1/2014

Virology Journal 1/2014 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.